Nanobodies as probes to investigate purinergic signaling

Marie Eggers; Felix Rühl; Friedrich Haag; Friedrich Koch-Nolte

doi:10.1016/j.bcp.2020.114394

Nanobodies as probes to investigate purinergic signaling

Standard

Nanobodies as probes to investigate purinergic signaling. / Eggers, Marie; Rühl, Felix; Haag, Friedrich ; Koch-Nolte, Friedrich.

In: BIOCHEM PHARMACOL, Vol. 187, 114394, 05.2021.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Eggers, M, Rühl, F, Haag, F & Koch-Nolte, F 2021, 'Nanobodies as probes to investigate purinergic signaling', BIOCHEM PHARMACOL, vol. 187, 114394. https://doi.org/10.1016/j.bcp.2020.114394

APA

Eggers, M., Rühl, F., Haag, F., & Koch-Nolte, F. (2021). Nanobodies as probes to investigate purinergic signaling. BIOCHEM PHARMACOL, 187, [114394]. https://doi.org/10.1016/j.bcp.2020.114394

Vancouver

Eggers M, Rühl F, Haag F , Koch-Nolte F. Nanobodies as probes to investigate purinergic signaling. BIOCHEM PHARMACOL. 2021 May;187. 114394. https://doi.org/10.1016/j.bcp.2020.114394

Bibtex

@article{c23ff500d6e644929ffd056e05ff9287,

title = "Nanobodies as probes to investigate purinergic signaling",

abstract = "Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD+-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.",

keywords = "Amino Acid Sequence, Animals, Antisense Elements (Genetics)/administration & dosage, Humans, Immunoglobulin Heavy Chains/genetics, Protein Structure, Tertiary, Purinergic Agonists/administration & dosage, Purinergic Antagonists/administration & dosage, Receptors, Purinergic/genetics, Signal Transduction/drug effects, Single-Domain Antibodies/administration & dosage",

author = "Marie Eggers and Felix R{\"u}hl and Friedrich Haag and Friedrich Koch-Nolte",

year = "2021",

month = may,

doi = "10.1016/j.bcp.2020.114394",

language = "English",

volume = "187",

journal = "BIOCHEM PHARMACOL",

issn = "0006-2952",

publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Nanobodies as probes to investigate purinergic signaling

AU - Eggers, Marie

AU - Rühl, Felix

AU - Haag, Friedrich

AU - Koch-Nolte, Friedrich

PY - 2021/5

Y1 - 2021/5

N2 - Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD+-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.

AB - Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD+-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.

KW - Amino Acid Sequence

KW - Animals

KW - Antisense Elements (Genetics)/administration & dosage

KW - Humans

KW - Immunoglobulin Heavy Chains/genetics

KW - Protein Structure, Tertiary

KW - Purinergic Agonists/administration & dosage

KW - Purinergic Antagonists/administration & dosage

KW - Receptors, Purinergic/genetics

KW - Signal Transduction/drug effects

KW - Single-Domain Antibodies/administration & dosage

U2 - 10.1016/j.bcp.2020.114394

DO - 10.1016/j.bcp.2020.114394

M3 - SCORING: Review article

C2 - 33388283

VL - 187

JO - BIOCHEM PHARMACOL

JF - BIOCHEM PHARMACOL

SN - 0006-2952

M1 - 114394

ER -